GlobeImmune, Inc.
New phase I cancer trial planned
Published in Oncology Business Week, June 27th, 2004
The U.S. Food and Drug Administration (FDA) has ended its 30-day review of the GlobeImmune's Investigational New Drug (IND) application for the GI-4000 product series, which paves the way for Phase I trial initiation. GlobeImmune's GI-4000 series is a class of targeted immunotherapy products under development for the treatment of a variety of cancers. This series was developed using a yeast-based immunotherapy platform and targets a protein called Ras that is mutated in a number of different types of tumors.
According to the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
More Articles from Oncology Business Week
- Adherex Technologies, Inc.
Biopharmaceutical company reports loss of $0.02 per share - Attenuon, L.L.C.
Phase I trial of ATN-224 initiated in patients with solid tumors - Cepheid
NCI $1.9M grant awarded for GeneXpert platform research - Favrille, Inc.
FDA issues special protocol assessment for phase III trial of FavId - HealthEast
First Minnesota hospital to use robot-assisted technology in prostate cancer surgery - MedPanel, Inc.
Life sciences research and information company launches new publication - More from this issue of Oncology Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
